Common BRCA1 Variants and Transcriptional Activation  by MONTEIRO, ALVARO N.A. et al.
Letters to the Editor
Am. J. Hum. Genet. 61:761–762, 1997
Common BRCA1 Variants and Transcriptional which when activated produces b-galactosidase) with
the following constructs (all in the context of aa 1560–Activation
1863): (a) the wild-type BRCA1 sequences; (b) an un-To the Editor:
classiﬁed variant suspected to be a disease predisposingGerm-line mutations in BRCA1 account for a portion
mutation Ser1613Cys (Breast Cancer Information Coreof breast and ovarian cancer predisposition (Easton et
1997); (c) a polymorphism at the same positional. 1993; Miki et al. 1994). BRCA1 encodes a 1,863–
Ser1613Gly; and (d) a polymorphism Met1652Ile,amino acid protein, with tumor-suppression function,
which does not correlate with disease predispositionsince tumors in BRCA1-linked families show loss of
(Breast Cancer Information Core 1997). Our previousheterozygosity in the BRCA1 locus, retaining the mutant
data have indicated that a yeast-based assay gives theallele (Smith et al. 1992; Neuhausen and Marshall
same results as the mammalian transfection system1994). In addition, Scully et al. (1997) have shown that
(Monteiro et al. 1996).BRCA1 interacts in vivo with Rad51, suggesting a role
As expected, the wild-type BRCA1 C-terminus acti-for BRCA1 in the maintenance of genome integrity. Re-
vated transcription of both reporter genes (table 1). Thecently, we and others have demonstrated that the
Ser1613Cys mutation, which is suspected to be corre-BRCA1 C-terminal acidic region can act as a transcrip-
lated with disease predisposition, did not show activa-tional activation domain in vivo when fused to a heterol-
tion of either gene. On the other hand, both commonogous DNA binding domain (Monteiro et al. 1996;
variants of BRCA1 showed wild-type activity in all theChapman and Verma 1996). We have also shown that
reporter genes tested.missense germ-line mutations found in breast and ovar-
ian cancer patients abolish transcription activation. The
C-terminus encompasses a domain recently deﬁned as
Table 1the BRCT domain (Koonin et al. 1996), which is found
in several proteins involved in the control of cell cycle.
Transcriptional Activation by Common Variants of BRCA1
We hypothesize that BRCA1 can act as a transcriptional
activator and that loss of this function predisposes the HF7c HF7c SFY526
(Liquid) (Solid) (b-Galactosidase)carrier to disease.
We investigated whether common variants found in
Wt (aa1560–1863) / (1.0) / /the general population and not correlated with disease
Ser1613Cys 0 (0) 0 0
predisposition would also activate transcription. To do Ser1613Gly / (1.0) / /
this, we created fusions of GAL4 DNA binding domain Met1652Ile / (1.0) / /
(pGBT9 vectors) and BRCA1 fragments (amino acids
NOTE.—S. cerevisiae carrying the indicated fragments and mutants[aa] 1560–1863), consisting of the previously identiﬁed
were assayed for growth in the absence of histidine, both in liquid andtransactivation domain (Monteiro et al. 1996). We
on solid medium (HF7c) and also for production of b-galactosidase
transformed yeast strains (HF7c and SFY526) con- (SFY526). Cultures were grown as described byMonteiro et al. (1996).
taining two reporter genes (HIS3, which when activated Relative activity is shown in parenthesis. Several (4–8) independent
clones were assayed for each construct.allows growth in the absence of histidine, and lacZ,
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K, Tavtigian S, Liu Q, et al (1994) A strong candidate forIt is interesting to note that in a recent report, Dunning
the breast and ovarian cancer susceptibility gene BRCA1.et al. (1997) examined whether common BRCA1 vari-
Science 266:66–71ants could confer modest individual risk as opposed to
Monteiro ANA, August A, Hanafusa H (1996) Evidence forthe highly penetrant mutations found in multiple case
a transcriptional activation function of BRCA1 C-terminalfamilies of early onset of breast and ovarian cancer.
region. Proc Natl Acad Sci USA 93:13595–13599
Examining four polymorphisms, one of which is in the Neuhausen SL, Marshall CJ (1994) Loss of heterozygosity in
C-terminal region (Ser1613Gly, the same mutation used familial tumors from three BRCA1-linked kindreds. Cancer
here), Dunning et al. concluded that haplotypes con- Res 54:6069–6072
taining these variants do not contribute signiﬁcantly to Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J,
disease predisposition. Our data agree with this analysis, Ashley T, et al (1997) Association of BRCA1 with Rad51
in mitotic and meiotic cells. Cell 88:265–2758since the construct containing this variant had wild-type
Smith SA, Easton DF, Evans DGR, Ponder BAJ (1992) Alleleactivity in our assay.
losses in the region 17q12-21 in familial breast and ovarianIn conclusion, we show here that two common vari-
cancer involve the wild-type chromosome. Nat Genet 2:ants of BRCA1 that do not contribute to disease predis-
128–131position show wild-type transcriptional activity. More-
over, our results strongly suggest that the Ser1613Cys
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lieve these results provide additional indication that York, NY 10021.
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use of the yeast transcription assay to predict disease 0002-9297/97/6103-0033$02.00
predisposition conferred by mutations found in the C-
terminal region.
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